Erdem-Eraslan Lale, Heijsman Daphne, de Wit Maurice, Kremer Andreas, Sacchetti Andrea, van der Spek Peter J, Sillevis Smitt Peter A E, French Pim J
Department of Neurology, Be 430A, Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
J Neurooncol. 2015 May;122(3):461-70. doi: 10.1007/s11060-015-1741-1. Epub 2015 Feb 19.
Causal genetic changes in oligodendrogliomas (OD) with 1p/19q co-deletion include mutations in IDH1, IDH2, CIC, FUBP1, TERT promoter and NOTCH1. However, it is generally assumed that more somatic mutations are required for tumorigenesis. This study aimed to establish whether genes mutated at low frequency can be involved in OD initiation and/or progression. We performed whole-genome sequencing on three anaplastic ODs with 1p/19q co-deletion. To estimate mutation frequency, we performed targeted resequencing on an additional 39 ODs. Whole-genome sequencing identified a total of 55 coding mutations (range 8-32 mutations per tumor), including known abnormalities in IDH1, IDH2, CIC and FUBP1. We also identified mutations in genes, most of which were previously not implicated in ODs. Targeted resequencing on 39 additional ODs confirmed that these genes are mutated at low frequency. Most of the mutations identified were predicted to have a deleterious functional effect. Functional analysis on a subset of these genes (e.g. NTN4 and MAGEH1) showed that the mutation affects the subcellular localization of the protein (n = 2/12). In addition, HOG cells stably expressing mutant GDI1 or XPO7 showed altered cell proliferation compared to those expressing wildtype constructs. Similarly, HOG cells expressing mutant SASH3 or GDI1 showed altered migration. The significantly higher rate of predicted deleterious mutations, the changes in subcellular localization and the effects on proliferation and/or migration indicate that many of these genes functionally may contribute to gliomagenesis and/or progression. These low-frequency genes and their affected pathways may provide new treatment targets for this tumor type.
1p/19q共缺失的少突胶质细胞瘤(OD)中的因果性基因改变包括IDH1、IDH2、CIC、FUBP1、TERT启动子和NOTCH1的突变。然而,一般认为肿瘤发生需要更多的体细胞突变。本研究旨在确定低频突变的基因是否可参与OD的起始和/或进展。我们对3例1p/19q共缺失的间变性OD进行了全基因组测序。为了估计突变频率,我们对另外39例OD进行了靶向重测序。全基因组测序共鉴定出55个编码突变(每个肿瘤8 - 32个突变),包括IDH1、IDH2、CIC和FUBP1中的已知异常。我们还鉴定出了一些基因中的突变,其中大多数以前未被认为与OD有关。对另外39例OD的靶向重测序证实这些基因以低频发生突变。鉴定出的大多数突变预计具有有害的功能效应。对这些基因的一个子集(如NTN4和MAGEH1)的功能分析表明,突变影响蛋白质的亚细胞定位(n = 2/12)。此外,与表达野生型构建体的细胞相比,稳定表达突变型GDI1或XPO7的HOG细胞显示出细胞增殖改变。同样,表达突变型SASH3或GDI1的HOG细胞显示出迁移改变。预测的有害突变率显著更高、亚细胞定位的变化以及对增殖和/或迁移的影响表明,这些基因中的许多在功能上可能有助于胶质瘤的发生和/或进展。这些低频基因及其受影响的途径可能为这种肿瘤类型提供新的治疗靶点。